Repository logo
 

$\textit{Drosophila}$ vinculin is more harmful when hyperactive than absent, and can circumvent integrin to form adhesion complexes

Published version
Peer-reviewed

Change log

Authors

Maartens, AP 
Wellmann, J 
Wictome, E 
Green, H 

Abstract

Vinculin is a highly conserved protein involved in cell adhesion and mechanotransduction, and both gain and loss of its activity causes defective cell behaviour. Here, we examine how altering vinculin activity perturbs integrin function within the context of Drosophila development. Whereas loss of vinculin produced relatively minor phenotypes, gain of vinculin activity, via a loss of head-tail autoinhibition, caused lethality. The minimal domain capable of inducing lethality is the talin-binding D1 domain, and this appears to require talin-binding activity, as lethality was suppressed by competition with single vinculin binding sites from talin. Activated Drosophila vinculin triggered the formation of cytoplasmic adhesion complexes via the rod of talin, but independently of integrin. These complexes contain a subset of adhesion proteins but no longer link the membrane to actin. The negative effects of hyperactive vinculin were segregated into morphogenetic defects caused by the whole head domain, and lethality caused by the D1 domain. These findings demonstrate the critical importance of the tight control of vinculin's activity.

Description

Keywords

Adhesion, $\textit{Drosophila}$, Vinculin, Integrin, Talin, Rhea, Protein complex

Journal Title

Journal of Cell Science

Conference Name

Journal ISSN

0021-9533
1477-9137

Volume Title

29

Publisher

The Company of Biologists
Sponsorship
Biotechnology and Biological Sciences Research Council (BB/L006669/1)
Biotechnology and Biological Sciences Research Council (BB/D526102/1)
Wellcome Trust (092096/Z/10/Z)
Wellcome Trust (086451/Z/08/Z)
Cancer Research Uk (None)
This work was supported by grants from the Biotechnology and Biological Sciences Research Council (BBSRC) (BB/L006669/1 to N.H.B. and studentship BB/D526102/1 to J.W.) and the Wellcome Trust (086451 to N.H.B.), and Gurdon Institute core funding from the Wellcome Trust (092096) and Cancer Research UK (C6946/A14492).